Patient monitoring and education over a tailored digital application platform for congenital heart disease: A feasibility pilot study

Nashat, Heba; Habibi, Hajar; Heng, Ee Ling; Nicholson, Conor; Gledhill, Jonathan; Obika, Bernard Dillon; Yassaee, Arrash; Markides, Vias; McCleery, Piers

doi:10.1016/j.ijcard.2022.05.002

Cited by 3 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cardiovascular disease‐focused trials focused on managing heart failure, vascular disease, ventricular contractions, myocardia, hypotension, atrial fibrillation, and coronary heart disease. Within this category, the DTx were personalized to patient education of their disease state 83 and remote monitoring to lower the number of emergency department visits 84 . The musculoskeletal‐related trials indicated generalized pain osteoarthritis, musculoskeletal disease, general arthritis, among other diseases.…”

Section: Digital Therapeutics In Active Clinical Trialsmentioning

confidence: 99%

“…Within this category, the DTx were personalized to patient education of their disease state 83 and remote monitoring to lower the number of emergency department visits. 84 The musculoskeletal‐related trials indicated generalized pain osteoarthritis, musculoskeletal disease, general arthritis, among other diseases. In these cases, DTx can be designed as guided exercises in VR as part of the rehabilitation process 85 , 86 or through the use of AI to create a tailored pain management plan based on patient progress.…”

Section: Digital Therapeutics In Active Clinical Trialsmentioning

confidence: 99%

See 1 more Smart Citation

Digital therapeutics in the clinic

Phan

Mitragotri

Zhao

2023

Bioengineering & Transla Med

View full text Add to dashboard Cite

Digital therapeutics are emerging as a new form of therapeutic interventions. Unlike conventional therapeutics, digital therapeutics deliver interventions directly to patients using an evidence‐based, clinically evaluated software to treat, manage, or prevent diseases. Digital therapeutics manifest in diverse forms such as web‐based applications, mobile applications on smart devices, virtual reality, and video games. As its own product category for FDA approval, digital therapeutics can function as stand‐alone treatments or in combination with conventional therapeutics to improve adherence and/or efficacy. Here, we review the clinical landscape of digital therapeutics. We summarize FDA‐approved products and their clinical use, overview >300 ongoing clinical trials, and discuss challenges for their clinical translation and strategies to overcome the same.

show abstract

Section: Digital Therapeutics In Active Clinical Trialsmentioning

confidence: 99%

Section: Digital Therapeutics In Active Clinical Trialsmentioning

confidence: 99%

Digital therapeutics in the clinic

Phan

Mitragotri

Zhao

2023

Bioengineering & Transla Med

View full text Add to dashboard Cite

show abstract

“…Moreover, the birth prevalence of CHD has increased by 4.2% (17,876 cases per 100,000 babies) ( 1 ). Recent diagnostic and therapeutic advances have also increased the number of adults with CHD ( 2 – 4 ). Furthermore, the prevalence of CHD differs among different regions and countries ( 5 ), but what is common among adults with CHD is the fact that they all have to deal with sequelae such as heart failure (HF), endocarditis, arrhythmias, and pulmonary hypertension, which can result from multiple medical and surgical treatments received in previous years ( 6 , 7 ).…”

Section: Introductionmentioning

confidence: 99%

Quality of life in adult patients with congenital heart disease: Results of a double-center study

et al. 2023

View full text Add to dashboard Cite

IntroductionPrevalence of congenital heart disease (CHD) has increased in recent years, and patients with CHD have to deal with sequelae of the multiple medical and surgical treatments that can affect different aspects of their life which could be reflected in their quality of life (QoL). In Iran, to the best of our knowledge, QoL of adult patients with CHD has not been investigated, so this study aimed to investigate the QoL of adult patients with CHD referred to two Iranian outpatient settings.MethodsIn 2022, a double center, cross-sectional study was performed on adult patients with CHD receiving out-patient care at Besat Clinic in Kerman, Iran, and Clinic of Shahid Rajaee Hospital in Tehran, Iran. Inclusion criteria were documented diagnosis of CHD based on guidelines, ejection fraction of above 45% and age of 18–55 years. We recruited a sample of 120 individuals using a simple random sampling method. At the day of referring to the adult congenital heart diseases clinic, after ensuring their written consent to participate in the study, we asked patients to fill in two questionnaires of demographic questionnaire and Persian version of the Ferrans and Powers Quality of Life Index. Data were analyzed using descriptive statistics and chi square via SPSS-22.ResultsA total of 101 patients with a mean age of 31.05 years participated in the study. Demographic and socio-economic factors had no significant relationship with the patients’ QoL. But factors related to the disease were significantly different among QoL groups (P-value > 0.05).DiscussionAdults with CHD had a low QoL, which is not related to their demographic and socio-economic factors. That is, the existence of the disease alone and its accompanying complications can affect the QoL of these people. Hence, the mental health of adult patients with CHD should be monitored during their routine cardiac care.

show abstract